ERBB2 and endometrial serous adenocarcinoma: Clinical research, including the trial by Fader et al. (2020), has demonstrated that HER2-targeted therapy can improve outcomes in HER2-positive uterine serous carcinoma, reinforcing the relevance of HER2 as a clinically actionable biomarker [13].